Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.32 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.31 |
| ▸ | IL1B | P01584 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL476823 | 0.96 | HPGD (0.40) | HPGDALDH1A1ESR1P2RX7JAK2 | |
| SCHEMBL114987 | 0.84 | ALDH1A1 (0.33) | ALDH1A1ABL1ADORA3CYP2C19ADORA2A | |
| SCHEMBL113156 | 0.79 | POLB (0.41) | ALDH1A1ABL1SMN1; SMN2 | |
| SCHEMBL14300762 | 0.77 | ALDH1A1 (0.36) | HPGDALDH1A1ABL1ADORA3CYP2C19 | |
| SCHEMBL476859 | 0.76 | ABL1 (0.30) | ABL1 | |
| SCHEMBL31638156 | 0.75 | FLT3 (0.33) | ABL1YTHDC1CYP2C19MCL1 | |
| SCHEMBL31178702 | 0.74 | ALDH1A1 (0.33) | HPGDALDH1A1YTHDC1CYP2C19SMN1; SMN2 | |
| SCHEMBL31179099 | 0.74 | ABL1 (0.35) | ALDH1A1ESR1ABL1CYP2C19SMN1; SMN2 | |
| SCHEMBL31127814 | 0.73 | RET (0.32) | CYP2C19 | |
| SCHEMBL29131777 | 0.72 | YTHDC1 (0.36) | HPGDALDH1A1ABL1YTHDC1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411398-B1 | METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2014-12-17 | — | — | EP | disclosed |
| EP-2411398-B1 | METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-8785651-B2 | Method for manufacturing a boronic acid ester compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| US-8785651-B2 | Method for manufacturing a boronic acid ester compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| US-8785651-B2 | Method for manufacturing a boronic acid ester compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| EP-2214675-B1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | GENENTECH INC (US) | 2013-11-20 | — | — | EP | disclosed |
| US-20130109852-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130109852-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-20130109852-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-02 | — | — | US | disclosed |
| US-8431694-B1 | Process for making thienopyrimidine compounds | GENENTECH, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120123122-A1 | METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND | GENENTECH, INC. (US) | 2012-05-17 | — | — | US | disclosed |
| EP-2411398-A1 | METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2012-02-01 | — | — | EP | disclosed |
| US-20100292468-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | GENETECH, INC | 2010-11-18 | — | — | US | disclosed |
| US-20100292468-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | GENETECH, INC | 2010-11-18 | — | — | US | disclosed |
| US-20100292468-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | GENETECH, INC | 2010-11-18 | — | — | US | disclosed |
| WO-2010110782-A1 | METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010110782-A1 | METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-09-30 | — | — | WO | disclosed |
| EP-2214675-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | Genentech, Inc. (US) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009055730-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | GENENTECH, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009055730-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | GENENTECH, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292468-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | PIK3CA, PIK3CD, PIK3CB | HPGD 1109/4885ALDH1A1 1766/4885ESR1 3272/4885 |
| US-20130109852-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | PIK3CA, PIK3CD, PIK3CB | HPGD 1043/4885ALDH1A1 1780/4885ESR1 3347/4885 |
| US-20120123122-A1 | METHOD FOR MANUFACTURING A BORONIC ACID ESTER COMPOUND | NISCH, BRSK1, BLK | HPGD 3061/4885ALDH1A1 4174/4885ESR1 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.